You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for New Drug Application (NDA): 021992


✉ Email this page to a colleague

« Back to Dashboard


NDA 021992 describes PRISTIQ, which is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the PRISTIQ profile page.

The generic ingredient in PRISTIQ is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
Summary for 021992
Tradename:PRISTIQ
Applicant:Pf Prism Cv
Ingredient:desvenlafaxine succinate
Patents:1
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 021992
Suppliers and Packaging for NDA: 021992
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992 NDA Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 0008-1210 0008-1210-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1210-30)
PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992 NDA Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 0008-1211 0008-1211-01 90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1211-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 50MG BASE
Approval Date:Feb 29, 2008TE:ABRLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Jul 5, 2027Product Flag?Substance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 100MG BASE
Approval Date:Feb 29, 2008TE:ABRLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Jul 5, 2027Product Flag?Substance Flag?YDelist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 25MG BASE
Approval Date:Aug 20, 2014TE:ABRLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Jul 5, 2027Product Flag?Substance Flag?YDelist Request?

Expired US Patents for NDA 021992

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.